CNI Stroke Center
701 East Hampden Ave., Suite 415
Englewood, CO 80113
Phone: (303) 597-1724
Fax: (303) 788-7666
E-mail Us
Swedish Medical Center and CNI's Stroke Center form the only Accredited
Comprehensive Stroke Center in the region
|
Stroke Research at CNI
with Swedish Medical Center
The CNI Stroke Center, under the direction of Dr. Don B. Smith, and in
conjunction with Swedish Medical Center, is involved in the following
clinical trials. For more information on the criteria for each of these
studies, go to www.StrokeCenter.org/Trials.
TRA 2oP – TIMI50®
This trial is researching the efficacy and safety of a novel investigational anti-platelet agent in preventing a recurrent stroke.
The hope: Doctors will be able to utilize a safer, more effective medication in trying to preventing future strokes
IMS-III®
This trial examines whether combined intravenous (IV) and intra-arterial (IA) treatment is superior to standard IV rt-PA alone when started within three hours of stroke onset.
The hope: Doctors will be able to determine which treatment may lead to a more favorable outcome in stroke patients who present within 3 hours of symptom onset.
TNK S2B®
This trial compares the safety and efficacy of Tenecteplase (TNK) and Alteplase (rt-PA) in ischemic stroke patients who can be treated within 3 hours of symptom onset.
The hope: Doctors may be able to utilize a more effective treatment in managing stroke in patients who arrive to the hospital within 3 hours after their symptoms begin.
SAMMPRIS®
This trial compares the safety and efficacy of current intensive medical therapy alone to that combined with intracranial angioplasty and stenting in preventing stroke.
The hope: Patients who suffer from intracranial stenosis and are at high risk for stroke may have a reduced risk as a result of this procedure.
|
Did You Know...
We treat more than 20% of stroke patients with IV t-PA compared
with 5% for patients across the U.S.
Less than 5% of stroke patients across the country currently receive
intravenous t-PA for acute ischemic stroke (caused from a blood clot),
mostly due to missing the window of opportunity for treatment (must be
less than 3 hours from stroke onset to safety administer t-PA).
Intravenous (IV) t-PA given through a vein/systemically is currently the
only FDA approved treatment for stroke.
In contrast, Swedish Medical Center is treating more than 20% of stroke
patients with IV t-PA. In part, this is because of our efficient "Stroke
Alert" system that provides coordinated, aggressive treatment for
stroke patients and because our physicians have the experience
to identify when t-PA, a complex drug, can be safely administered.
Other Research Efforts:
 Finding treatments
that we can give at longer time periods after stroke symptom onset.
Developing more
powerful and safer medications to prevent, treat and rehabilitate
stroke victims.
Using technology,
like interventional/minimally invasive techniques, to treat the stroke
from within the artery (currently can use intra-arterial t-PA directly
on a clot; a corkscrew-like device to pull out a clot; or a new "Wingspan"
stent to bolster blood flow and prevent a stroke).
|
